The PennZone

  • Home
  • Non-profit
  • Books
  • Health
  • Business
  • Entertainment
  • Marketing
  • Legal
  • Women

FDA Panel Overwhelmingly Rejects MDMA Psychedelic as Mental Health Treatment
The PennZone/10273696

Trending...
  • Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
  • Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
  • Coach Bulinda Wright Advances To Top Five In National 'Top Host 2026 Competition'
FDA Panel Overwhelmingly Rejects MDMA Psychedelic
CCHR applauds the panel's decision amid concerns over biased clinical trials and risks such as heart attacks, strokes, psychosis, and sexual abuse of patients during prescribed psychedelic trips.

LOS ANGELES - PennZone -- A panel of experts from the Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee has overwhelmingly rejected the use of the psychedelic MDMA, also known as Ecstasy and Molly, for post-traumatic stress disorder (PTSD), after finding that its purported efficacy in clinical trials does not outweigh the risks.[1] MDMA is currently illegal in the U.S. and the FDA has so far never approved the therapeutic use of the mind-altering drug.[2] The mental health industry watchdog, Citizens Commission on Human Rights International, wants it to stay that way, warning against adding any psychedelic drugs to the number of prescription psychotropics already in use.

FDA staff said MDMA may raise the risk of heart attacks and strokes by increasing patients' pulse and blood pressure. They also cited the vulnerability of patients under the influence of the drug. "We are particularly concerned that serious harm could result" and "may include, but are not limited to, events resulting in hospitalization or death, events that put patients at risk for hospitalization or death, and events with significant negative consequences."[3]

The Institute for Clinical and Economic Review (ICER), an independent scientific group that evaluates treatments and their prices, earlier raised questions about the research behind MDMA. In a vote, advisers to ICER decided nearly unanimously that the alleged benefits of the drug had not been proven.[4] ICER highlighted the placebo bias and ethical concerns in the data presented to the FDA. Furthermore, "Based on public reports, there is no question that, despite the trial requiring dual treatment by one male and one female therapist, boundaries, including sexual boundaries, were severely crossed with at least one patient…. Nearly everyone we spoke with discussed how MDMA breaks down barriers, heightens suggestibility, and creates a substantial risk with any therapists who might choose to take advantage of patients."[5]

Kim Witczak, the FDA's advisory panel's consumer representative, said: "I have real concerns with the validity of the data and the allegations of misconduct. I can't in good conscience support something where this many harms are being reported and just say, 'Oh, someone somewhere is investigating it.'"[6]

The company which made the application to the FDA for MDMA approval and is now fielding criticism over the integrity of its clinical trial data discussed at the FDA hearing. It had raised $100 million in financing in an attempt to win FDA approval.

More on The PennZone
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • Veteran Antiques Expert John Swahn Releases New Book: The Truth About Antiques
  • Steven Weisz of Art Imagined Photography to exhibit at ExpoMetro Florence, Italy

Shares for companies focused on psychedelic drugs plummeted following the FDA panel's decision.  It is seen as a setback, hitting investor confidence in an array of publicly traded companies working to bring psychedelics to clinics, market researchers say. MDMA and other psychedelics have been projected to be $10 billion a year industry.[7]

The drug already has a particularly bad side effect profile. The National Institute of Drug Abuse warns MDMA causes involuntary jaw clenching, illogical or disorganized thoughts, panic attacks and in severe cases, a loss of consciousness and seizures. MDMA is also addictive, can interfere with the body's ability to regulate temperature, and can raise heart rate to a dangerous level.[8]

The Drug Enforcement Administration warns ecstasy—the street name for MDMA—can cause "confusion, anxiety, depression, paranoia, sleep problems, and drug craving," which may last weeks after ingestion.[9]

Yet psychedelics are marketed as the alternative for antidepressants, which have in recent years been exposed in the media and in drug regulatory agency warnings as having side effects such as suicide, cardiac problems, sexual dysfunction, severe withdrawal effects and lack of efficacy.[10] This has inadvertently given license to psychedelic pushers and manufacturers to advocate psychedelics as alternatives.

U.S. psychiatrist Paul S. Appelbaum wrote that the risks go beyond altered perceptions or changes to personality to include acute and sustained psychiatric symptoms, including severe anxiety and the possibility of triggering manic or psychotic episode.

CCHR says that replacing antidepressants with psychedelics is like switching seats on the Titanic, adding that the marketing gimmicks used to "sell" psychedelics imply the drugs are harmless, calling them "natural medicines," referring to psilocybin and mescaline, while synthetic psychedelics include MDMA and LSD.[11]

Jan Eastgate, President of CCHR International, warns, "If approved, they would likely then be promoted on TV direct-to-consumer marketing, giving the drugs a tacit 'approval' that they are safe to take, and, therefore also safe to abuse." Already, in 2022, it was estimated that around 2.1 million people in the U.S. had used ecstasy in the previous year, with the highest percentage of those aged 18 to 25.[12]

In 2022, Colorado enacted the Natural Medicine Health Act (NMHA), which provides psychedelics for adults 21 years and older, passing it off "equitable access to natural psychedelic medicine." In March 2024, the Colorado Office of Natural Medicine released draft regulations for those administering psilocybin, outlining training needed in order to obtain a license. In an audacious move, some proponents have argued that, as the drug has "spiritual properties," any government regulation could violate First Amendment constitutional rights—freedom of religion.[13]

More on The PennZone
  • Hope Survives Managing Director Jasmine Balignasay-Chavez Receives 2026 Catalyst Award
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Kellyn Co-Founder Meagan Grega Named President-Elect of the American College of Lifestyle Medicine
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award

CCHR condemns what it views as a profit-driven scheme, using unscientific marketing and invoking the need for constitutional protection. They draw parallels to the late 1980s when SSRI antidepressants were marketed as correcting a "chemical imbalance" in the brain—a claim now definitively proven false.

Forbes reports prescription sales for antidepressants are estimated to be $50 billion and "while biotech analysts say that FDA-approved psychedelic-assisted therapy, with drugs like psilocybin and MDMA, could seize $10 billion in annual sales by targeting the treatment-resistant depression subcategory, the real opportunity lies in replacing drugs like Prozac, Zoloft and other selective serotonin reuptake inhibitors."[14]

CCHR urges further rejection of psychedelic drug applications, warning that the current push for these substances is a hallmark of profit-driven tactics by the pharmaceutical industry, psychiatrists, and unregulated psychedelic clinics—ultimately exposing Americans to more damaging mind-altering drugs.

About CCHR: CCHR was founded in 1969 by the Church of Scientology and the late Dr. Thomas Szasz, Professor of Psychiatry, State University of New York Upstate Medical University. It has helped achieve over 190 laws that protect patients from coercive psychiatric practices.

[1] www.msn.com/en-us/health/other/fda-staff-raises-concerns-about-ecstasy-drug-s-safety-in-report/ar-BB1nozAn; www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-flags-concerns-mdma-assisted-ptsd-treatment-2024-05-31/; www.nature.com/articles/d41586-024-01622-3

[2] www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-flags-concerns-mdma-assisted-ptsd-treatment-2024-05-31/

[3] www.msn.com/en-us/health/other/fda-staff-raises-concerns-about-ecstasy-drug-s-safety-in-report/ar-BB1nozAn

[4] www.msn.com/en-us/health/other/fda-staff-raises-concerns-about-ecstasy-drug-s-safety-in-report/ar-BB1nozAn

[5] psychedelicalpha.com/wp-content/uploads/2024/03/PTSD_Draft-Report_For-Publication_03262024.pdf

[6] www.biopharmadive.com/news/mdma-fda-advisers-vote-lykos-post-traumatic-stress-disorder-ptsd/718011/

[7] www.forbes.com/sites/willyakowicz/2021/06/23/the-future-of-psychedelic-medicine-might-skip-the-trip-rick-doblin-bryan-roth-mindmed-darpa-maps/?sh=d69e851244fd

[8] www.cchrint.org/2020/05/12/repurposing-psychotropic-drugs-to-treat-physical-ills-puts-patients-in-danger/ citing www.drugabuse.gov/publications/research-reports/mdma-ecstasy-abuse/what-are-effects-mdma; www.medicalnewstoday.com/articles/297064#fast-facts-on-mdma; nida.nih.gov/sites/default/files/1763-mdma-ecstasy-abuse.pdf

[9] www.cchrint.org/2015/05/28/psychiatryecstacycampaign/ citing www.dea.gov/sites/default/files/2020-06/Ecstasy-MDMA-2020_0.pdf

[10] www.cchrint.org/2024/06/07/high-antidepressant-use-calls-for-a-de-prescribing-de-escalation-policy/

[11] herb.co/learn/whats-the-difference-between-natural-vs-synthetic-psychedelics; www.dlapiper.com/en/insights/publications/2023/01/state-psychedelic-regulation-oregon-and-colorado-taking-the-lead

[12] www.addictiongroup.org/resources/mdma-statistics/

[13] psychedelicstoday.com/2023/11/17/harming-while-healing-the-oppressive-nature-of-psychedelic-centric-drug-policy/; www.axios.com/local/denver/2024/03/07/colorado-draft-rules-psychedelic-healing-centers; digitalcommons.wku.edu/cgi/viewcontent.cgi?article=1828&context=stu_hon_theses

[14] www.forbes.com/sites/willyakowicz/2021/06/23/the-future-of-psychedelic-medicine-might-skip-the-trip-rick-doblin-bryan-roth-mindmed-darpa-maps/?sh=d69e851244fd

Contact
Amber Rauscher
***@cchr.org


Source: Citizens Commission on Human Rights
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
  • Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
  • Meals on Wheels of the Greater Lehigh Valley Raises Over $50,000 to Help Feed Local Seniors
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
  • The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
  • New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
  • Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
  • Coach Bulinda Wright Advances To Top Five In National 'Top Host 2026 Competition'
  • Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
  • Feldman Shepherd Named as 2027 'Best Law Firm' by Best Lawyers -- Tier 1 National & Philadelphia
  • The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
  • Corner Property Management AAMC Awarded Community Management Contract for Belvidere at Doyle Square
  • Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
  • TrueDriveCost Launches Free Calculators for the Real Cost of Owning a Car
  • A New Era Of Social Networking Is Here !
  • Poetry Quarterly Returns in Print With Its Fall 2026 Issue, Featuring 42 Poets
  • HIRO Ostomy Belt Launch by Richard O'Hamill

Popular on PennZone

  • ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection - 170
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs - 156
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal - 147
  • What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type - 142
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta - 132
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of - 131
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client - 117
  • Sycamore Dove Releases "Loving Every Moment" - 116
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders

Similar on PennZone

  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Kellyn Co-Founder Meagan Grega Named President-Elect of the American College of Lifestyle Medicine
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us